Invention Grant
- Patent Title: Heterocyclic compound
-
Application No.: US15538297Application Date: 2015-12-21
-
Publication No.: US10202376B2Publication Date: 2019-02-12
- Inventor: Eiji Kimura , Yuhei Miyanohana , Masaki Ogino , Yuta Tanaka , Makoto Fushimi , Tomohiro Okawa , Yuki Hanya , Tatsuki Koike
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agency: Foley & Lardner LLP
- Priority: JP2014-259662 20141224
- International Application: PCT/JP2015/085689 WO 20151221
- International Announcement: WO2016/104434 WO 20160630
- Main IPC: C07D471/04
- IPC: C07D471/04 ; A61K31/437 ; C07D487/04 ; A61P25/00 ; A61P29/00

Abstract:
Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.
Public/Granted literature
- US20170362223A1 HETEROCYCLIC COMPOUND Public/Granted day:2017-12-21
Information query